- Home
- NVAX vs DFIN Comparison
NVAX vs DFIN Comparison
Compare NVAX & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- DFIN
- Stock Information
- Founded
- NVAX 1987
- DFIN 1983
- Country
- NVAX United States
- DFIN United States
- Employees
- NVAX N/A
- DFIN N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- DFIN Other Consumer Services
- Sector
- NVAX Health Care
- DFIN Consumer Discretionary
- Exchange
- NVAX Nasdaq
- DFIN Nasdaq
- Market Cap
- NVAX 2.0B
- DFIN 1.9B
- IPO Year
- NVAX 1995
- DFIN N/A
- Fundamental
- Price
- NVAX $8.57
- DFIN $60.68
- Analyst Decision
- NVAX Buy
- DFIN Strong Buy
- Analyst Count
- NVAX 6
- DFIN 3
- Target Price
- NVAX $17.83
- DFIN $76.33
- AVG Volume (30 Days)
- NVAX 3.3M
- DFIN 220.6K
- Earning Date
- NVAX 02-26-2025
- DFIN 02-18-2025
- Dividend Yield
- NVAX N/A
- DFIN N/A
- EPS Growth
- NVAX N/A
- DFIN 18.18
- EPS
- NVAX N/A
- DFIN 3.18
- Revenue
- NVAX $885,193,000.00
- DFIN $802,100,000.00
- Revenue This Year
- NVAX N/A
- DFIN $1.75
- Revenue Next Year
- NVAX N/A
- DFIN $4.27
- P/E Ratio
- NVAX N/A
- DFIN $19.71
- Revenue Growth
- NVAX N/A
- DFIN 1.74
- 52 Week Low
- NVAX $3.53
- DFIN $56.02
- 52 Week High
- NVAX $23.86
- DFIN $71.01
- Technical
- Relative Strength Index (RSI)
- NVAX 48.28
- DFIN 45.11
- Support Level
- NVAX $7.62
- DFIN $60.24
- Resistance Level
- NVAX $8.67
- DFIN $63.74
- Average True Range (ATR)
- NVAX 0.46
- DFIN 1.61
- MACD
- NVAX -0.03
- DFIN 0.08
- Stochastic Oscillator
- NVAX 44.60
- DFIN 16.28
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a global risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( US), Europe, Asia, Canada, and others, of which the US accounts for the vast majority of its total revenue.